A “checkpoint inhibitor” such as anti-CTLA-4 and anti-PD/PD-L1 binds with these co-inhibitory checkpoint molecules and counter-inhibits the downregulation of T effector function, hence reinstating anti-tumour activity. This evidence concerns the gene CTLA4 and neoplasm.